API-0002

10/716,175

IN THE CLAIMS

Ex-A

1. (Currently Amended) A pharmaceutical composition comprising a compound of Formula 1 in a therapeutically effective amount of





Formula I

or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier or excipient, wherein

A_1 is ~~an optionally substituted di-allylamine,~~ an optionally substituted aryl group, ~~an optionally substituted 5- or 6- membered heteroaryl group, an optionally substituted bicyclic heteroaryl group having a 5-membered heteroaryl ring fused to a phenyl ring, an optionally substituted partially unsaturated or aromatic heterocyclic group having two 6-membered rings, an optionally substituted 5- to 7-membered heterocycloalkyl group containing at least one nitrogen atom and 0 or 1 additional heteroatoms, an optionally substituted partially unsaturated 5- to 7-membered heterocycloalkyl group containing at least one nitrogen atom and 0 or 1 additional heteroatoms, a 5- or 6-membered heterocycloalkyl group fused to a phenyl or heteroaryl ring, or a fused or spiro 8 to 11 membered bicyclic heterocycloalkyl group containing at least one nitrogen atom and 0 to 3 additional heteroatoms~~;

A_2 is

(i)



(ii)



~~wherein when V is absent, W is absent;~~

~~Z is carbonyl, thiocarbonyl, or imino;~~ and

R_1 and R_2 are each independently hydrogen, ~~or~~ C_1-C_6alkyl, C_2-C_6alkenyl, or C_2-C_6alkynyl,

~~R_1 and R_2 are independently C_1-C_6alkyl, C_2-C_6alkenyl, or C_2-C_6alkynyl, each of which is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, C_1-C_4alkoxy, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy, or~~

~~R_1 and R_2 are joined to form a 5- to 7-membered saturated or mono-unsaturated ring optionally containing one additional heteroatom chosen from N, S, and O, which 5- to 7-membered saturated or mono-unsaturated ring is substituted with 0 to 3 substituents independently chosen from halogen, hydroxy, amino, C_1-C_4alkyl, C_1-C_4alkoxy, mono- and di-(C_1-C_4alkyl)amino, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy.~~

Claims 3-12. (Canceled)

13. (Currently Amended) A ~~compound or salt~~ pharmaceutical composition according to Claim ~~6~~ 2 in which R_1 and R_2 are independently hydrogen, methyl, or ethyl.

14. (Currently Amended) A ~~compound or salt~~ pharmaceutical composition according to Claim 13 in which R_1 and R_2 are both hydrogen.

Claims 15-16. (Canceled).

17. (Currently Amended) A ~~compound or salt~~ pharmaceutical composition according to Claim ~~6~~ 2 wherein

EXA

A_1 is aryl, ~~a partially-unsaturated heterocyclic group, or heteroaryl group;~~

substituted with 0 to 5 substituents independently chosen from:

(a) halogen, hydroxy, cyano, amino, nitro, oxo, -COOH, $-CONH_2$, $-SO_2NH_2$, -SH, C_1-C_2haloalkyl, and C_1-C_2haloalkoxy, and

(b) C_1-C_6alkyl, C_2-C_6alkenyl, C_2-C_6alkynyl, C_1-C_6alkoxy, C_2-C_6alkenyloxy, C_1-C_4alkoxy(C_1-C_4alkyl), amino(C_1-C_6)alkyl, mono- and di-(C_1-C_6alkyl)amino, mono- and di-(C_1-C_4alkyl)aminoC_1-C_4alkyl, C_2-C_6alkanoyl, C_2-C_8alkanoyloxy, C_1-C_8alkoxycarbonyl, mono- and di-(C_1-C_6alkyl)carboxamide, (C_3-C_7cycloalkyl)carboxamide, mono- and di-(C_1-C_6alkyl)sulfonamide, C_1-C_6alkylthio, aryl(C_0-C_4alkyl)thio, C_1-C_6alkylsulfinyl, and C_1-

API-0002

Claims 22-54. (Canceled).

Ed. A

55. (Currently Amended) A ~~compound or salt~~ pharmaceutical composition according to Claim 2 comprising Compound of the formula ~~Formula 27, wherein~~



~~Formula 27~~



wherein

R_{18} represents 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, amino, nitro, C_1-C_4alkyl, C_1-C_4alkoxy, mono- and di-(C_1-C_4alkyl)amino, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, and phenyl.

Claims 56 – 80. (Canceled)

81. (Currently Amended) ~~A compound or~~ pharmaceutically ~~acceptable salt thereof, in which the compound is selected from~~ The pharmaceutical composition of Claim 1 in which the compound is

~~1-(Furan-2-carbonyl)-3-(4-benzo[*d*]thiazol-2-yl-phenyl)-thiourea;~~

~~1-(Benzofuran-2-yl-carbonyl)-3-[5-(benzo[*d*]oxazol-2-yl)-2-methyl]phenylthiourea;~~

~~1-(3-(Benzo[*d*]thiazol-2-yl)phenyl)-3-(2-phenoxyacetyl)-thiourea;~~

~~1-(4-(Benzo[*d*]oxazol-2-yl)phenyl)-3-propionylthiourea;~~

~~1-(Pyridin-3-carbonyl)-3-(4-benzo[*d*]thiazol-2-yl-phenyl)-thiourea;~~

~~1-[3-(2-chlorophenyl-5-methyl-isoxazol-4-yl)-carbonyl]-3-(4-isopropylphenyl)thiourea;~~

~~Butyl4-(3-(2-phenoxyacetyl)-thioureido)benzoate;~~

~~Butyl-4-(3-acetylthioureido)benzoate;~~

~~Butyl-4-(3-(2-(3-chlorophenoxy)-acetyl)-thioureido)benzoate;~~

~~Butyl-4-(3-(3-phenoxypropanoyl)-thioureido)benzoate;~~

~~1-(3-(Piperidin-1-yl)propanoyl)-3-(4-pentylphenyl)thiourea;~~

~~1-(3-(Piperidin-1-yl)propanoyl)-3-(4-(pentyloxy)phenyl)thiourea;~~

~~1-(3-(Piperidin-1-yl)propanoyl)-3-(3-phenoxyphenyl)thiourea;~~

~~1-(3-Morpholinopropanoyl)-3-(4-(pentyloxy)phenyl)thiourea;~~

~~1-(1-Methylpiperidin-3-yl-carbonyl)-3-(4-(pentyloxy)phenyl)thiourea;~~

~~1-(1-Methylpiperidin-3-yl-carbonyl)-3-(4-(pentyloxy)phenyl)thiourea;~~

~~1-(2-(2-methylpiperidin-1-yl)acetyl)-3-(4-(pentyloxy)phenyl)thiourea;~~

~~1-(2-Oxo-4-phenyl-pyrolidin-1-ylcarbonyl)-3-(3-benzyloxy-phenyl)thiourea; and~~

~~1-(5-Trifluoromethoxy-benzofuran-2-yl-carbonyl)-3-(3-benzyloxy-phenyl)thiourea.~~

Claims 82-86. (Canceled)

87. (Currently Amended) A method for treating Hepatitis C infection comprising administering to a patient in need of such treatment a therapeutically effective amount of ~~a compound or salt~~ the pharmaceutical composition according to Claim 1.

Claims 88-90. (Canceled)

Pharmaceutical Composition Comprising therapeutically effective amount of a

91. (New) A compound of the formula

Ex. A1



or a pharmaceutically acceptable salt thereof, wherein

R_1 and R_2 are independently hydrogen, methyl, or ethyl;

R_{16} is 1 to 3 substitutents independently chosen from hydroxy, cyano, amino, nitro, C_1-C_4alkyl, C_1-C_4alkoxy, mono- and di-(C_1-C_4alkyl)amino, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, and phenyl;

A_2 is a group of the formula

API-0002







wherein

R_{11} and R_{13} each represent 0 to 3 substituents independently chosen from halogen, hydroxy, cyano, C_1-C_6alkyl, C_1-C_6alkoxy, mono- and di-(C_1-C_6alkyl)amino, C_2-C_6alkanoyl, C_1-C_2haloalkyl, C_1-C_2haloalkoxy, and phenyl; and

R_{13} and R_{14} are independently chosen at each occurrence from hydrogen and C_1-C_4alkyl.

92. (New) A method for treating Hepatitis C infection comprising administering to a patient in need of such treatment a therapeutically effective amount of ~~a compound or salt of~~ Claim 91.

Ex. A

Pharmaceutical Composition according to